<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02241395</url>
  </required_header>
  <id_info>
    <org_study_id>NGBSI-09</org_study_id>
    <nct_id>NCT02241395</nct_id>
  </id_info>
  <brief_title>Cell Therapy as Treatment for Cerebral Palsy</brief_title>
  <official_title>Autologous Bone Marrow Mononuclear Cell Therapy in Cerebral Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neurogen Brain and Spine Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neurogen Brain and Spine Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to study the effect of autologous bone marrow mononuclear cells
      on common symptoms of cerebral palsy patients.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in clinical symptoms over a period of 2 years</measure>
    <time_frame>2 years</time_frame>
    <description>Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in GMFM score</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gross Motor Function Measure</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Stem Cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intrathecal autologous bone marrow mononuclear cell transplantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Intrathecal autologous bone marrow mononuclear cell transplantation</intervention_name>
    <arm_group_label>Stem Cell</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed cases of any type of Cerebral Palsy

          -  age above 6 months.

        Exclusion Criteria:

          -  presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/
             Hepatitis C Virus

          -  malignancies

          -  bleeding tendencies

          -  pneumonia

          -  renal failure

          -  severe liver dysfunction

          -  severe anemia [Hemoglobin &lt; 8]

          -  any bone marrow disorder

          -  space occupying lesion in brain

          -  other acute medical conditions such as respiratory infection and pyrexia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neurogen brain and spine institute</name>
      <address>
        <city>Navi Mumbai</city>
        <state>Maharashtra</state>
        <zip>400706</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 12, 2014</study_first_submitted>
  <study_first_submitted_qc>September 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>October 23, 2018</last_update_submitted>
  <last_update_submitted_qc>October 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebral Palsy</keyword>
  <keyword>autologous bone marrow mononuclear cells</keyword>
  <keyword>stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

